The historical rank and industry rank for Radius Health's EV-to-EBIT or its related term are showing as below:
RDUS's EV-to-EBIT is not ranked *
in the Drug Manufacturers industry.
Industry Median: 17.125 * Ranked among companies with meaningful EV-to-EBIT only.
The historical data trend for Radius Health's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Radius Health's EV-to-EBIT
For the Drug Manufacturers - Specialty & Generic subindustry, Radius Health's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Radius Health's EV-to-EBIT Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Radius Health's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Radius Health's EV-to-EBIT falls into.
Radius Health EV-to-EBIT Calculation
Radius Health's EV-to-EBIT for today is calculated as:
Radius Health's current Enterprise Value is $747.9 Mil.
Radius Health's EBIT for the trailing twelve months (TTM) ended in Jun. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-49.9 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Radius Health (NAS:RDUS) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Radius Health's Enterprise Value for the quarter that ended in Jun. 2022 was $761.6 Mil.
Radius Health's EBIT for the trailing twelve months (TTM) ended in Jun. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-49.9 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Radius Health EV-to-EBIT Related Terms
Thank you for viewing the detailed overview of Radius Health's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.
Radius Health (Radius Health) Business Description
Radius Health Inc is an integrated biopharmaceutical company. It develops and commercializes endocrine therapeutics in the areas of osteoporosis and oncology. The company's product, TYMLOS, is for the treatment of postmenopausal women with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, multiple risk factors for fracture, or patients who have failed or are intolerant to other available osteoporosis therapy. The product pipeline of the company includes Abaloparatide-patch for the treatment of postmenopausal women with osteoporosis, Elacestrant, and RAD140. It primarily operates the business in the United States of America and generates key revenue from the sales of TYMLOS.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
RDUS has been successfully added to your 